Abstract: The invention concerns compositions with antimicrobial activity.These compositions contain a benzoic acid derivative with the formula: ##STR1## in which: A represents a straight or branched alkyl chain with 3 to 4 carbon atoms,X represents the oxygen atom or a direct bond,R represents hydrogen or an alkyl group with 2 to 6 carbon atoms, possibly substituted by an alcohol function and a salt of such a derivative.Applications: drugs, disinfectants and preservative agents.

Abstract: The present invention relates to new aromatic derivatives of formula: ##STR1## wherein: Alk is an alkylene group with 1 to 10 carbon atoms,R.sub.1 is hydrogen or an alkyl with 1 to 6 carbon atoms,R.sub.2 and R.sub.3 are similar or different and represent a cycloalkyl with 3 to 6 carbon atoms or a striaght or branched alkyl with 1 to 6 carbon atoms, either substituted or non-substituted by a phenyl or methyl phenyl group, or R.sub.2 and R.sub.3 form, together with the atom of nitrogen to which they are bonded, a mono-nitrogenous heterocycle containing no other heteroatom, such as pyrrolidino, piperidino, azepino, hexamethylene-imino, 4-methyl-piperidino, 4-phenyl-piperidino, 1,2,3,4-tetrahydro-2-isoquinolyl, 4-benzyl-piperidino;R.sub.4 is hydrogen, halogen, methyl or phenyl,R.sub.5 is hydrogen, halogen or methyl,or R.sub.4 and R.sub.5 together with the benzene ring to which they are bonded, constitute a 1-naphthyl or 2-naphthyl group,and the pharmaceutically acceptable salts with mineral or organic acids.

Abstract: A process for the synthesis, in liquid phase and by fragments, of hGRF 1-44 and hGRF 1-40. This process consists in coupling, one after the other and in the order of the sequence of the GRF,(1) on the one hand, the following fragments:__________________________________________________________________________ H--Ala--Arg--Ala--Arg--Leu--NH.sub.2 called Fragment A hGRF (40-44) or alaninamide (40) H--Gln--Glu--Arg--Gly--OH called Fragment B'.sub.1 hGRF (36-39) H--Glu--Ser--Asn--OH called Fragment B'.sub.2 hGRF (33-35) H--Ser--Arg--Gln--Gln--Gly--OH called Fragment C hGRF (28-32) H--Leu--Gln--Asp--Ile--Met--OH called Fragment D' hGRF (23-27) H--Arg--Lys--Leu--OH called Fragment E'.sub.1 hGRF (20-22) __________________________________________________________________________to obtain the peptide K.sub.

Abstract: The present invention relates to benzamidine derivatives corresponding to the general formula ##STR1## in which: A represents a linear or branched alkyl chain containing from 3 to 9 carbon atoms; andX represents the oxygen atom or a direct bond, with the restriction that if X represents a direct bond, the benzamidine and the alkanol group are located in the para position, and also the pharmaceutically acceptable salts of the products of the formula (I);it also relates to a process for the preparation of the products of the formula (I) and the drugs for external use which contain a product of the formula (I).

Abstract: A process for the synthesis, in liquid phase and by fragments, of hGRF 1-44 and hGRF 1-40. This process consists in coupling, one after the other and in the order of the sequence of the GRF,(1) on the one hand, the following fragments:______________________________________ H--Ala--Arg--Ala--Arg--Leu--NH.sub.2 called hGRF Frag- (40-44) or ment A alaninamide (40) H--Gln--Glu--Arg--Gly--OH called hGRF Frag- (36-39) ment B'.sub.1 H--Glu--Ser--Asn--OH called hGRF Frag- (33-35) ment B'.sub.2 H--Ser--Arg--Gln--Gln--Gly--OH called hGRF Frag- (28-32) ment C H--Leu--Gln--Asp--Ile--Met--OH called hGRF Frag- (23-27) ment D' H--Arg--Lys--Leu--OH called hGRF Frag- (20-22) ment E'.sub.1 ______________________________________to obtain the peptide K.sub.1 [(hGRF (20-44)] on the corresponding peptide having the sequence (20-40) and(2) on the other hand, the following fragments: ______________________________________ H--Gln--Leu--Ser--Ala called hGRF Frag- (16-19) ment F.sub.

Abstract: The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising: coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group; selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.

Abstract: The invention relates to novel thiosulfonate derivatives of general formu a:R--S--SO.sub.2 --R.sub.1in which R represents a 1H-imidazol-2-yl, quinolin-2-yl, 5-amino-1,3,4-thiadizol-2-yl or 4,5-dihydro-thiazol-2-yl radical and R.sub.1 represents a lower alkyl, (hydroxy)lower alkyl, phenyl, (lower alkyl) phenyl, (hydroxy lower alkyl) phenyl, (lower alkanoyl) phenyl or quinolin-8-yl radical.The thiosulfonate derivatives in question exert an inhibitory action with respect to the malformation or destruction of red blood corpuscules due to a genetic modification of haemoglobin or to parasites and can, therefore, be used in the treatment of drepanocytosis, malaria and babebiosis.

Abstract: The invention relates to pharmaceutical or veterinary compositions for initing the malformation or destruction of red blood corpuscules due to a genetic modification of haemoglobin or to parasites, compositions comprising, as active ingredient, at least one thiosulfonate derivative of general formula:R--S--SO.sub.2 --R.sub.1in which R represents a 1-methyl-imidazol-2-yl, 1H-benzimidazol-2-yl or benzoxazol-2-yl radical and R.sub.1 represents a lower alkyl, (hydroxy) lower alkyl, lower alkanoyl, phenyl, (lower alkyl) phenyl, (hydroxy lower alkyl) phenyl, (lower alkanoyl) phenyl or quinolin-8-yl radical.The compositions in question can be used in the treatment of drepanocytosis, malaria and babebiosis.

Abstract: Benzoic acid derivatives with the general formula: ##STR1## in which: A represents a straight or branched alkyl chain with 5 to 10 carbon atoms,X represents the oxygen atom or a direct bond,R represents hydrogen or an alkyl group with 2 to 6 carbon atoms, possibly substituted by an alcohol function,and the salts of the said derivatives.These derivatives display antimicrobial activity and are suitable as antiseptics, disinfectants and preservatives, particularly in the fields of pharmaceuticals, cosmetology and agri-foodstuffs.

Abstract: The invention relates to the peptides of the formula: ##STR1## in which: R.sub.1 represents hydrogen or a protecting group for the amine group, such as t-butoxycarbonyl, benzyloxycarbonyl or lower alkanoyl groups;X represents beta-alanine glycine or a direct bond between R.sub.1 and the amine group; andR.sub.2 represents a group chosen from: ##STR2## corresponding to the side chains of the natural amino acid leucine, methionine and norleucine.These peptides inhibit gastric secretion.

Abstract: The invention relates to the peptides of the formula: ##STR1## in which: R represents hydrogen or a protecting group for the terminal amine group, such as t-butoxycarbonyl (Boc), benzyloxycarbonyl (Z) or lower alkanoyl;X.sub.1 represents either beta-Ala or a direct bond between R and the terminal amine group of the amino acid TRP;TRP denotes either the L isomer or the D isomer of tryptophan;X.sub.2 represents L-leucine, L-methionine or L-norleucine; andY denotes hydrogen, a halogen atom (preferably fluorine or chlorine), a trifluoromethyl group, a cyano group or a nitro group.These peptides inhibit gastric secretion.

Abstract: The present invention relates to cyclic dithiodiacetamides with action inhibiting the malformation or the destruction of the red blood corpuscles due to a genetic modification of the haemoglobin or to parasites, of formula: ##STR1## in which X is a direct bond, an atom of oxygen or of sulfur, a methylene group, an ethylene group or an N--R group, where R is an atom of hydrogen or a lower alkyl group, lower (hydroxy)alkyl group, lower alkanoyl group or a phenyl group; to their possible pharmaceutically acceptable salts; to a process for preparing them from a dithiodiacetate or a mercaptoacetate of lower alkyl by transamination and possible oxidation; and to pharmaceutical compositions containing them as active ingredients, useful for the treatment for example of drepanocytosis, or sickle cell anaemia, of malaria and of babebiosis.

Abstract: The invention relates to peptides of general formula:R--A--Gly--Trp--B--Asp--NH.sub.2 (I)in which:Asp NH.sub.2 represents the amide in .alpha. position of the aspartic acid of formula: ##STR1## R represents hydrogen, a protector group of the terminal amine function such as t.butyloxy carbonyl (BOC), benzyloxy carbonyl (Z), lower alkanoyl,A designates:either tyrosine, tyrosine-O-sulfate, threonine or methionine;or a dipeptide selected from: --Ala--TYR--, --TYR--Thr--, --TYR Met--, TYR designating either of the 2 amino-acids tyrosine or tyrosine-O-sulfate;or a tripeptide selected from: --Glu--Ala--TYR--, Asp--TYR--Thr--, --Asp--TYR--MET--;or a tetrapeptide selected from: --Glu--Glu--Ala--TYR--, --Gln Asp--TYR--Thr--, --Arg--ASP--TYR--Met--;or a pentapeptide selected from: --Glu--Glu--Glu--Ala--TYR--, --Pyr--Gln--Asp--TYR--Thr--, --Asp--Arg--Asp--TYR--Met;B designates methionine, leucine or norleucine.

Abstract: Benzodiazepines of formula ##STR1## wherein R3 is methyl or ethyl and R4 is chlorine or fluorine are useful therapeutic agents for the treatment of neuropsychic disturbances.

Abstract: The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising:--coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group;--selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and--eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.

Abstract: The present invention discloses a 4-[3-(1,1-dimethyl-2-3(3-indolyl)ethylamino)-2-hydroxypropoxy]indole of formula ##STR1## and pharmaceutically acceptable acid salts thereof, which are particularly active on the cardiovascular system.

Abstract: The present invention relates to novel products, responding to general formula: ##STR1## in which R.sub.1 and R.sub.2 taken together represent an atom of oxygen .dbd.O or R.sub.1 represents hydrogen and R.sub.2 represents an OH radical, R.sub.3 designates an atom of hydrogen or a straight or branched alkyl radical, or an alkynyl group having from 1 to 6 atoms of carbon, R.sub.4 represents a straight or branched alkyl radical having from 1 to 6 atoms of carbon, R.sub.5 designates an atom of hydrogen, an alkyl group having from 1 to 4 atoms of carbon or an acylamine group and n=3 or 4; as well as to the acid addition salts of said products, to a process for preparing said products and to drugs, particularly active on the cardiovascular system, containing at least one of said products.

Abstract: The present invention relates to the chemical products of general formula: ##STR1## in which R.sub.1 and R.sub.2 designate hydrogen; halogen, lower alkyl or lower alkoxy; R.sub.3 and R.sub.4 designate hydrogen, alkyl, alkoxy, halogen, nitro, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, a (CH.sub.2).sub.n COOR, (CH.sub.2).sub.2 CONHR, (CH.sub.2).sub.n NHCOOR or (CH.sub.2).sub.n NHCOR group; or R.sub.3 and R.sub.4 together form a heterocycle bonded to the benzene cycle; X.sub.1 is hydrogen, alkyl, hydroxymethyl or COOR and X.sub.2 is hydrogen or methyl; and to the pharmaceutically acceptable salts of said products. It also relates to a process for preparing said products and to the drugs active in particular on the cardiovascular system, containing at least one of said products.

Abstract: The present invention relates to new pyridine derivatives of formula: ##STR1## wherein R.sub.1 is an alkyl or an alicyclic group, R.sub.2 and R.sub.3 are alkyls or alicyclic groups or form an heterocycle with the atom of nitrogen to which they are bonded; the invention also relates to a process for the preparation of said derivatives and the medicines containing at least one of the said derivatives.

Abstract: The present invention relates to phenoxypropane having the formula ##STR1## in which R.sup.1 and R.sup.2 are like or unlike and each is an alkyl group having 1-4 carbon atoms, R.sup.3 is hydrogen or an alkyl group having 1-4 carbon atoms, R.sup.4 is a halogen atom, preferably fluorine, chlorine or bromine, including their optical isomers and also their addition salts with acids.These compounds are of therapeutic value in the treatment of cardiovascular conditions.The invention also relates to methods of synthesis of these products including a synthesis which involves the production, as a intermediate of an 8-aza-4,9-dioxa-2,3-benzo-bicyclo-[4,2,1]-octane having the formula ##STR2## in which R.sup.1 and R.sup.4 are as above defined.